Australia’s TGA to Review Advertising of Stem Cell Therapies

April 08, 2021

Australia’s Therapeutic Goods Administration (TGA) is investigating the advertising of stem cell therapies to ensure that content in the public domain complies with the Australian rules for advertising therapeutic goods. In Australia, the term “stem cell therapies” often refers to autologous human cell and tissue therapies.

Under Australia’s Therapeutic Goods Act 1989, criminal offenses and civil penalties can apply where a person advertises or promotes the use of human cell and tissue products to the public, including autologous human cell and tissue products that are exempt or excluded from being included in the Australian Register of Therapeutic Goods

In its announcement, the TGA noted that consumers who have not found relief from the symptoms of a health condition through conventional means may be vulnerable to claims about emerging stem cell treatments not included in the register. The agency asks that Australians who see an advertisement for stem cells or autologous human cell and tissue products submit a report to the TGA using an online form.